Skip to main content
Erschienen in:

01.03.2023

Pregnancy Health Among Breast Cancer Survivors: Development and Validation of an Educational Package in Iran

verfasst von: Marzieh Azizi, Elham Ebrahimi, Zahra Behboodi Moghadam, Zohreh Shahhosseini, Maryam Modarres

Erschienen in: Journal of Cancer Education | Ausgabe 4/2023

Einloggen, um Zugang zu erhalten

Abstract

Reproductive-aged breast cancer (BC) survivors are concerned about their fertility potential after BC treatment. No specific and comprehensive educational and clinical package examines pregnancy health in BC survivors. This study aimed to develop and validate a pregnancy health educational package for BC survivors who intend to experience pregnancy after completing cancer treatment. The present study is a mixed methods study conducted in three phases. The researchers, in phase 1, performed a qualitative content analysis study to explore the perceived needs and experiences of pregnancy among Iranian BC survivors. Then in the second phase, the authors conducted a systematic literature review to search all available packages, guidelines, documents, and published papers on pregnancy or fertility status among BC survivors worldwide. In the third phase, the intervention type was selected according to the opinions of the expert’s team during two sessions of online meetings using the Delphi technique. The package quality was assessed by an expert team using the Appraisal of Guidelines for Research and Evaluation Instrument II (AGREE II) tool. The pregnancy health package for BC survivors was developed in seven separate chapters based on the qualitative study and literature review findings. The results of the validity or quality assessment of the package according to the six domains of the AGREE II tool were reported as follows: the score for the scope and purpose domain was 95.55%, the stakeholder involvement domain was 89.16%, the score for the rigor of development domain was 92.97%, clarity of presentation domain was 94.44%, the score of applicability domain was 87.06%, and the score of editorial independence domain was calculated 93.75%. The pregnancy health package was designed with high quality and validity and, as an excellent cost-effective resource, is proposed to BC survivors to increase their awareness regarding their fertility issues before attempting to conceive.
Anhänge
Nur mit Berechtigung zugänglich
Literatur
12.
Zurück zum Zitat Runowicz CD, Leach CR, Henry NL, Henry KS, Mackey HT, Cowens-Alvarado RL et al (2016) American cancer society/American society of clinical oncology breast cancer survivorship care guideline. CA: Can J Clin 66:43–73 Runowicz CD, Leach CR, Henry NL, Henry KS, Mackey HT, Cowens-Alvarado RL et al (2016) American cancer society/American society of clinical oncology breast cancer survivorship care guideline. CA: Can J Clin 66:43–73
13.
Zurück zum Zitat Polit DF, Beck CT (2009) Essentials of nursing research: appraising evidence for nursing practice. Lippincott Williams & Wilkins Polit DF, Beck CT (2009) Essentials of nursing research: appraising evidence for nursing practice. Lippincott Williams & Wilkins
Metadaten
Titel
Pregnancy Health Among Breast Cancer Survivors: Development and Validation of an Educational Package in Iran
verfasst von
Marzieh Azizi
Elham Ebrahimi
Zahra Behboodi Moghadam
Zohreh Shahhosseini
Maryam Modarres
Publikationsdatum
01.03.2023
Verlag
Springer US
Erschienen in
Journal of Cancer Education / Ausgabe 4/2023
Print ISSN: 0885-8195
Elektronische ISSN: 1543-0154
DOI
https://doi.org/10.1007/s13187-023-02275-y

Neu im Fachgebiet Onkologie

Fortgeschrittenes Melanom: Wann den Checkpoint-Inhibitor absetzen?

Eine ICI-Therapie sollte bei Betroffenen mit fortgeschrittenem Melanom mindestens ein Jahr fortgesetzt werden. Bei anhaltendem Ansprechen kann danach offenbar ohne hohes Risiko ein Therapieabbruch erwogen werden.

Positive Phase IIb-Studie zu mRNA-gestützter CAR-T bei Myasthenia gravis

Eine auf das B-Zell-Reifungsantigen gerichtete mRNA-basierte CAR-T-Zell-Therapie wurde jetzt in einer ersten Phase IIb-Studie zur Behandlung der generalisierten Myasthenia gravis mit Placebo verglichen.

NSCLC: Hirnmetastasen durch elektrische Felder eindämmen

Zur Behandlung von Hirnmetasen bei nicht-kleinzelligem Lungenkrebs (NSCLC) stehen verschiedene Optionen zur Verfügung. TTFields – eine lokoregionäre, nicht-invasive physikalische Therapie – könnte sich hier einreihen.

Kontrollkoloskopie nach Polypektomie: Wann ist eine zweite Untersuchung nötig?

Wann benötigen polypektomierte Patienten und Patientinnen mehr als eine endoskopische Nachsorgeuntersuchung? Eine Kohortenstudie aus Großbritannien legt eine konkrete Strategie nahe.

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.